ArticleFood science & nutrition2025
Aflatoxin M1 in Milk and Dairy Products in Birjand, Iran: A Contribution to Human Health Risk Assessment.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Aflatoxin M1 in Milk from South-Central and Northwest China: Prevalence and Integrated Risk Characterization for Different Age-Sex Groups of Consumers.Foods (Basel, Switzerland) · 2026Article
- Aflatoxin M1 in Milk and Dairy Products in Birjand, Iran: A Contribution to Human Health Risk Assessment.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the current research was to examine the AFM1 contents in 150 milk and dairy product samples (including raw milk, UHT milk, yogurt, ice cream, and pasteurized milk) marketed in Birjand, Iran. The samples were analyzed utilizing high-performance liquid chromatography with a fluorescence detector (HPLC-FLD). The total mean of AFM1 in the raw milk, UHT milk, pasteurized milk, yogurt, and ice cream was 50.22 ± 12.39 ng/L, 12.17 ± 5.52 ng/L, 35.49 ± 11.07 ng/L, 13.03 ± 4.06 ng/kg, and 116.79 ± 40.35 ng/kg, respectively. The AFM1 contents of all samples were within the US FDA standard limits (500 ng/kg). The amounts of AFM1 in 16 samples of ice cream exceeded the limits set by the Iran National Standard Organization (INSO, 100 ng/kg). The contents of AFM1 in 41 samples exceeded the EU regulation (50 ng/kg). Furthermore, the health risks resulting from AFM1 occurrence in samples were evaluated using the Monte Carlo simulation. The 95th percentile value of the hazard index (HI) and the margin of exposure (MoE) in total samples for children was 9.028 and 2206, respectively, while those for adults were 1.934 and 10,295. The 95th percentile value of quantitative liver cancer risk (CR) in total samples for children and adults was 0.261 and 0.056 cancers/year/per 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.